(UroToday.com) The treatment landscape for first-line therapy among patients with metastatic renal cell carcinoma (mRCC) has changed dramatically over the past 2 years. In 2018, the publication of the CheckMate214 data demonstrated a survival benefit for patients treated with nivolumab and ipilimumab compared with sunitinib in intermediate and poor-risk mRCC, ushering in the immunotherapy era for mRCC. The subsequent publication of the JAVELIN Renal 101, KEYNOTE-426, and CheckMate-9ER studies demonstrated the superiority of avelumab and axitinib, pembrolizumab and axitinib, and nivolumab and cabozantinib compared to sunitinib in this disease space. In a plenary abstract presentation in the Poster Highlights Session: Renal Cell Cancer – Clinical Trial Updates session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Dr. Plimack and colleagues provide an update on the KEYNOTE-426 study examining outcomes for patients who received pembrolizumab and axitinib and have completed two years of follow-up.